Fracdose Pth Injection contains Teriparatide, a recombinant form of parathyroid hormone, at a concentration of 750mcg per 3ml. It is primarily used to treat osteoporosis in patients at high risk of fractures by stimulating new bone formation. Teriparatide works by activating osteoblasts, the cells responsible for bone building, thereby increasing bone mineral density and reducing the likelihood of fractures in the spine and other bones. This injection is typically prescribed for postmenopausal women, men with osteoporosis, or individuals who have experienced fractures due to long-term corticosteroid use. Administered via subcutaneous injection, Fracdose Pth Injection is generally given once daily, with treatment duration usually limited to 18-24 months to minimize potential side effects. Common adverse effects may include nausea, dizziness, leg cramps, and injection site reactions. It is contraindicated in patients with hypercalcemia, bone malignancies, or a history of skeletal radiation therapy. Regular monitoring of calcium levels and bone density is recommended during treatment. Fracdose Pth Injection should be used under strict medical supervision to ensure optimal outcomes in bone health management and fracture prevention.